RiskAngle
Summer 2024InactiveAI medical summaries in minutes
Pressure-test this opportunity
Turn this teardown into a decision-ready prompt for ChatGPT, Claude, or your agent.
AI medical summaries in minutes
Turn this teardown into a decision-ready prompt for ChatGPT, Claude, or your agent.
If you only have a few minutes to spare, here’s what investors, operators, and founders should know about RiskAngle (S24).
RiskAngle was a two-person YC Summer 2024 company that turned long medical records into summaries for insurers and law firms. Its workflow targeted underwriting, claims, and legal case preparation, where staff must connect events across scanned, duplicated, and poorly structured files.[1]
The product found real use, but not venture-scale growth. Founder William Hu said a handful of clients processed more than 100,000 pages before the company was acquired and shut down in late 2025.[2] The question was whether a small vendor could turn that capability into repeatable distribution and workflow ownership before models made summarization easier to copy.
RiskAngle the independent startup is inactive, as YC records.[1] The website appears to continue under its acquirer, Rewisoft, which calls RiskAngle its first product.[3] That continuity should not be mistaken for evidence that the original company survived independently.
YC lists Bill Chen and William Hu as RiskAngle's former founders. Chen studied computer science at Columbia; Hu had worked at Robinhood and Retool.[1] Public sources do not establish how they met or divided responsibilities at formation.
Chen traced the problem to his family. In his post-YC reflection, he wrote, "Both my parents are life insurance brokers." A serious skiing-accident claim showed him the labor required for medical-record review.[4] The expensive work was assembling a defensible account from documents produced for other purposes.
The team entered YC in Summer 2024 with a concise proposition: fast, accurate summaries of unstructured medical records for insurance companies and law firms.[1] Hu later described having two co-founders at different points, then wrote, "for the past 9 months, I've been founding solo." During that period he built the product end to end and signed the first customers.[2] The available evidence does not clarify when each founder left, how those transitions affected sales, or whether the company raised money beyond YC.
The original product converted medical records into summaries for claims, underwriting, and legal preparation.[1] The current product shows how that idea expanded: users upload PDF, image, or scanned records, choose or define a report outline, generate a structured document, and inspect links back to source material.[7] Report types now include chronologies, radiology consult packages, and malpractice reports. A case-aware assistant answers questions across the record, while case-management features support legal, insurance, and long-term-care work.[7]
Source links let a reviewer challenge a date, diagnosis, or omission without re-reading every page. The current site also advertises deduplication and source verification, though those are vendor claims, not independently measured accuracy results.[8]
The product later added human service. Its concierge offer assigns a report writer, includes two revisions, and advertises turnaround in as little as two business days.[9] That is more than an add-on: it reveals where software alone may stop. High-stakes records need exception handling, judgment, and accountability. Public evidence does not show whether this service began before or after the acquisition.
RiskAngle targeted insurers and law firms, then broadened its displayed workflows to long-term-care and related case work.[1][7] The best fit was a team with large case files, repetitive chronology work, and a reviewer responsible for defending the result. No named customer, insurer, law firm, channel partner, or campaign was found. The website's scenarios are examples, not customer references.
No defensible market-size estimate was found. Public sources disclose neither customer counts beyond “a handful” nor spending, case volume, retention, or revenue. Any top-down estimate would confuse the broad cost of claims or legal work with the narrower budget available for record-review software.
The 2026 field includes specialized products rather than a single category winner. Brighterway says it processes more than 10 million pages per month for national workers-compensation claims organizations.[10] Docura Health focuses on workers-comp review and report drafting.[11] InPractice and ChronoLaw sell cited chronologies and case Q&A, while Abel spans document review for legal and insurance work.[12][13][14]
These are current comparables, not proof of direct competition in 2024. They show the strategic problem: generic summarization is becoming a feature, while value moves toward workflow depth, corrections, integrations, audit trails, and focused distribution.
RiskAngle's 2024 terms contemplated subscriptions and recurring payments.[5] Search-extracted current pricing lists $400 per month for 2,500 pages, $600 for 5,000 pages, and $800 for 10,000 pages, plus case-manager support at $20 per hour and a $100-per-report concierge option.[7] Those prices describe the acquired product's present offer, not necessarily the startup's historical pricing.
Funding, acquisition price, ARR, gross margin, retention, and profitability were not disclosed in the observed sources. Without those inputs, unit economics cannot be estimated responsibly. The mix of subscriptions and paid human review suggests a useful tension: automation can lower first-pass labor, but service may be required to make outputs acceptable in high-stakes cases.
Hu reported that a handful of clients processed more than 100,000 pages.[2] This proves meaningful use, but not repeatability. The evidence does not disclose how quickly volume accumulated, how it was distributed among clients, whether clients renewed, or whether usage produced positive margins.
The company crossed a real product threshold: customers entrusted it with substantial records. Yet Hu wrote that it "wasn't able to reach the escape velocity needed for venture-scale growth," then announced its acquisition and shutdown.[2] The attempted remedy visible in the evidence was founder-led execution: Hu built the product and signed customers while operating solo for nine months.[2] That proved demand but did not establish a scalable acquisition channel.
RiskAngle was built largely on Anthropic's API, according to Hu.[2] Claude 3.5 Sonnet launched in June 2024 with a 200,000-token context window and published pricing of $3 per million input tokens and $15 per million output tokens.[15] Claude 4 followed in May 2025 with stronger tool use and extended reasoning.[16] Better models helped RiskAngle, but they also reduced the cost for competitors to reproduce the visible act of summarization.
The non-obvious mechanism was a moving moat. Each model improvement increased quality while shifting value toward distribution, correction data, review operations, and auditable integration. The current product's source verification, case management, and concierge service answer that pressure, but public evidence does not establish whether the startup or its acquirer developed them.[8][9]
Medical and insurance records impose requirements beyond fluent output. HHS proposed stronger HIPAA Security Rule cybersecurity requirements on December 27, 2024, and the NAIC says its third-party AI working group formed in 2024 to address insurer use of external data and models.[17][18] A vendor must document access, provenance, retention, vendor risk, and human review while selling into institutions with slow procurement.
The strongest counter-explanation is founder capacity. Hu was solo for nine months, and a small team may have lacked sales coverage or time.[2] That mattered, but a general product spanning law, insurance, and long-term care also had to earn trust across different buyers while specialists concentrated workflow and distribution.
The acquisition therefore reads as two outcomes at once. The independent startup ended, but its product and domain may have retained enough value for Rewisoft to continue them.[3] No independent announcement, purchase price, or operating metrics were found, so the transaction cannot be classified as a financial success or distress sale.